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We report the effect of the stable expression of a 13 amino acid human fibronectin (FN) peptide (FN13) on the organization of the FN
extracellular matrix (ECM) and of FN integrin receptors (FNRs), in relationship with the inhibition of cellular invasion, in three FN-ECM
defective human tumor-derived cell lines: SK-Hep1C3, hepatoma, ACN, neuroblastoma, and SK-OV-3, ovary carcinoma. All these cell lines
stably expressing the FN13 peptide, organized an FN-ECM, disorganized αvβ1 integrins and inactivated the ILK pathway, with the loss of
secretion of MMP-9. This was associated with the inhibition of cell invasion in Matrigel matrix only in SK-Hep1C3 and ACN, but not in SK-OV-
3 cells. Analysis of the integrin receptors organization showed that the FN13 expressing cells SK-Hep1C3 and ACN organized αvβ3 integrins,
whereas SK-OV-3 organized αvβ5 dimers. The functional block of αvβ5 integrins, with an inactivating anti-αvβ5 antibody, led to the induction
of αvβ3 integrins also in SK-OV-3 cells, and to the inhibition of cell invasion. These data show that in the human tumor cells studied FN13
inhibits the in vitro invasion through the dissociation of αvβ1 dimers, leading to ILK pathway inactivation, only when the organization of αvβ3
integrins is induced in the plasma membrane.
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Fibronectin (FN) is an adhesive heterodimeric glycoprotein
present in the extracellular matrix (ECM) of connective tissues
in a fibrillar insoluble form and in the blood in a globular
soluble form [1,2]. FN organization into the ECM depends
either in vivo or in vitro on the binding to cell surface integrin
receptors [3]. Integrins are αβ transmembrane heterodimers
with specific ligand binding potential, which are involved in
structural and regulatory functions, such as linking ECM to
actin cytoskeleton and providing bidirectional transmission of
signals across the plasma membrane [4,5]. Ten different FN
integrin receptors (FNRs) are known. Different FNRs can be
organized by the same cell type, at least in vitro [5,6]. In
cultured fibroblasts, typically organizing an abundant ECM of⁎ Corresponding author. Tel.: +39 030 3717240/241; fax: +39 030 3701157.
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doi:10.1016/j.bbamcr.2007.02.007FN, the main FNR is the α5β1 integrin, whereas minor FNRs
are the αvβ3 integrin [7], the αvβ6, the αvβ1 and the αvβ5
integrins, major vitronectin receptors [3,5,6,8].
Integrins, through binding with ECM molecules, play
important roles in most biological processes, among which
cell adhesion, migration and proliferation [9,10]. ECM dis-
organization and reduction, integrins reassortment and decrease
have been associated with malignant transformation. A typical
feature of transformed cells is their reduced adhesion to solid
substrates and capability of growing in vitro in multilayered
foci. The decreased adhesion of tumorigenic cells, as well as
their enhanced motility, greatly depends on the reduction of the
FN-ECM and on the alteration of FNRs expression [2,11–15]. In
particular, the α5β1 integrin disappears from the surface of
Rous sarcoma virus (RSV) transformed cell lines [16] and is
reduced in many human and murine tumors [17–20]. Con-
versely, forced expression of α5β1 integrin in tumor cells
reduces their motility and tumorigenicity [21,22], while
decrease of α5β1 expression enhances the tumorigenicity of
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binding FN was observed in several tumors [24–29]. The αvβ3
integrin, predominantly, although not exclusively, found in
cancer cells and neovessels [30,31], is known to alter cell–ECM
interactions and to cause increased tumorigenicity, as well as
invasiveness of several cancer cells [4]. In particular, αvβ3 has
been shown to contribute to the migration, establishment and
growth of pulmonary metastatic melanoma lesions [32], to
increase invasiveness of cutaneous melanomas [33], prostatic
carcinoma cells [34], human breast cancer cells in nude mice
[35], and metastasis of human melanoma cells in nude mice
[36]. Expression of αvβ3 integrin in melanoma, glioma, breast
and ovarian cancer has been associated with malignant
progression [24,37–40]. Finally, αvβ3 integrins have been
implicated in tumor-induced angiogenesis [15].
Cancer development requiring the acquisition of growth-
factor and integrin anchorage independence has been associated
to integrin-linked kinase (ILK), an intracellular adaptor and
kinase that links integrins and growth factors to the actin
cytoskeleton and to a range of signalling pathways regulating
cell proliferation and invasion, angiogenesis, and apoptosis
[41]. In particular, increased levels of ILK have been detected in
various cancers, whereas the inhibition of ILK expression and
activity showed an antitumorigenic effect [41].
Addition of exogenous FN restoring an FN-ECM can revert
the transformed phenotype in some cases; in particular, FN
improves cell adhesion and induces ECM organization,
supporting the normal cell morphology [11,13,22,29,42].
Similar effects are obtained treating tumor cells with super-
fibronectin, a polymeric form of FN, obtained adding a 76
amino acid FN peptide, also defined anastellin [43], to purified
human FN [44] or only with anastellin [43]. Both super-
fibronectin and anastellin, through the organization of the FN-
ECM, inhibit tumor cell spreading and migration in vitro and
prevent tumor formation, metastasis and angiogenesis in treated
mice injected with tumor cells [43,45]. We described a 13 amino
acid FN peptide (FN13), inducing the organization of the FN-
ECM in defective RSV transformed chick embryo fibroblasts
and in some human tumor derived cell lines [42]. FN13 added to
the culture medium, enhanced the substratum adhesion of these
tumorigenic cells and inhibited their migration and invasion in
vitro. In order to understand the role of FN13 on the FN-ECM
organization, and its possible effect on FNR integrins modula-
tion, a construct stably expressing FN13 in human tumor
derived cells has been generated. The transfected tumor cells
organized the FN-ECM through the modulation of αv-contain-
ing FN integrin receptors and showed a significant reduction of
their invasive potential in vitro, when they organized αvβ3 –
but not αvβ5 – FNR, in association with ILK pathway
suppression.
2. Materials and methods
2.1. Cell lines and antibodies
The tumor cell lines were: SK-Hep1 clone 3 (SK-Hep1C3), obtained in our
lab by single cell cloning from the human liver adenocarcinoma-derived cell
line SK-Hep1 (ATCC, HTB-52, Rockville, MD); human neuroblastoma cellline ACN [46], human ovary adenocarcinoma SK-OV-3 (ATCC, HTB-77),
and human renal carcinoma ACHN (ATCC, CRL1611). SK-Hep1C3 cells
were grown in Earle's Minimal Essential Medium (MEM) (Invitrogen,
Carlsbad, CA), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 1%
(v/v) Na-piruvate and non-essential amino acids. ACN, SK-OV-3, and ACHN
cells were grown in RPMI 1640, McCoy's 5A medium, and MEM
(Invitrogen, Carlsbad, CA), respectively, supplemented with 10% FBS. All
cell lines were grown in the presence of 100 IU/ml penicillin and 100 μg/ml
streptomycin at 37 °C in a 5% CO2 incubator. The purified FN13 peptide
(AHEEICTTNEGVM) and the scrambled FN13 sequence peptide (ITCET-
NEGEVAMH, ScrFN13) were from Primm (Milan) [42]. In this work we used
the f33 anti-human FN (hFN) monoclonal antibody (mAb) recognizing an
epitope in the C-terminus of the 120–140 kDa catheptic human FN fragment
located downstream the collagen-binding FN domain [47] which contains the
FN13 peptide sequence [42], and the mAbs directed against human integrin
dimers or subunits: anti-α5β1 (clone JBS5), anti-αvβ3 (clone LM609), anti-
αvβ6 (clone E7P6), anti-αvβ5 (clone 15F11), recognizing an epitope not
influenced by the ligand, anti-αvβ5 (clone P1F6), and anti-β3 (clone BB10)
all provided by Chemicon Int., Inc. (Temecula, CA). The anti-αv (clone
p2W7), anti-β5 (clone E-19), and anti-β1 (clone K20) integrin subunits mAbs,
and the anti-α1 (clone R164), anti-α2 (clone H293), anti-α3 (clone I19), anti-
α5 (clone H104) polyclonal antibodies (Abs) were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Another anti-β1 (clone BV7) integrin
subunit mAb, used for immunoprecipitation and Western blotting, and the anti-
matrix metalloproteinase-9 (MMP-9) polyclonal antibody were from Abcam
(Cambridge, UK). The anti-β3 pY773 phosphospecific antibody was provided
by Biosource Int. Inc. (Camarillo, CA), the anti-β1 pS785 integrin subunit
mAb was from Novus Biologicals, Inc. (Littleton, CO), and the anti-human
ILK mAb (clone 65.1.9) was from Upstate (Lake Placid, NY).
2.2. Construction and stable expression of a 13 amino acids
FN peptide plasmid (pFN13)
A 144-bp mini-gene, encoding the FN secretion signal sequence followed by
the 13 amino acids (AHEEICTTNEGVM) of FN13 peptide [42] was
synthesized by PCR with specific primers on the pgHF3.7 plasmid [48], (Fig.
2A) and directly ligated into the eukaryotic pEF6/V5-His-TOPO™ expression
vector according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).
SK-Hep1C3, ACN, and SK-OV-3 cell lines were transfected with pFN13 or
pEF6/V5-His-TOPO™ empty vector using the DOTAP liposomal transfection
reagent (Roche Applied Science, Basel) and selected with blasticidine according
to the manufacturer's instructions (Invitrogen, Carlsbad, CA). Established cell
lines carrying integrated pFN13 construct (SK-Hep1C3pFN13, ACNpFN13,
SK-OV-3pFN13) or empty vector were expanded for subsequent experiments.
Total RNA and genomic DNA were isolated from all transfected and
untransfected cell lines grown for 72 h to confluence using TRIzol reagent
according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).
Reverse transcriptase (RT) reaction was performed using Moloney murine
leukemia virus-RT (Gibco BRL) on 3 μg of total RNA and random hexamers by
standard protocol.
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) amplification
was used to confirm adequate cDNA synthesis in the different cell lines. The
expression of the FN13 minigene was verified using the primer-set pFNfor/V5
(Fig. 2A). The plasmid-specific T7/V5 primers were used on empty vector
transfected cells (Fig. 2A). All amplified products were analyzed by 2,5%
agarose gel electrophoresis.
2.3. In vitro induction of FN organization by FN13
Human plasma FN (hFN) (New York Blood Center Inc.) was FITC-
labelled according to the supplier's instructions (Fluorotag FITC Conjugation
kit from Sigma Aldrich, Inc.). FITC-hFN [240 μg/ml in 2% bovine serum
albumin (BSA)] was incubated in the absence and in the presence of 40 μg/
ml FN13 or ScrFN13, at 37 °C for 20 h. Urea was added to stabilize the
multimers at a final concentration of 3 M; the multimers were loaded on Petri
dishes and, after 24 h at 37 °C, analyzed with a CCD black and white TV
camera mounted on a Zeiss Axiovert 10S/H fluorescence microscope (Carl
Zeiss Microlmaging, Göttingen) at 630×.
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Tumor-derived cells cultured in the absence and in the presence of 40 μg/ml
purified FN13 peptide and tumor cells transfected with the empty cloning vector
or with pFN13 plasmid were seeded on glass coverslips and grown for 48 h to 8
days in complete medium. To analyze the FN-ECM organization, the cells,
cultured to confluence, were washed in PBS, methanol-fixed 2×20 min at
− 20 °C, air dried and immunoreacted with f33 anti-human FNmAb diluted 1:10
in 0.3% BSA, 0.01% NaN3 for 30 min at room temperature.
The α5β1, αvβ3, αvβ5, and αvβ6 integrin receptors analysis was
performed 48 h after seeding. To analyze α5β1 and αvβ3 integrins, the cells
were fixed in 3% paraformaldehyde and 60 mM sucrose for 7 min and
permeabilized in 0.5% (v/v) Triton X-100 for 90 s. After 2×5 min washing in
PBS, 0.15 M glycine, the cells were reacted for 30 min at room temperature with
4 μg/ml anti-α5β1, or anti-αvβ3 integrin mAbs diluted in 1% BSA, 0.01%
NaN3. To analyze αvβ5 and αvβ6 integrins, the cells were fixed in ice-cold
acetone for 10 min at − 20 °C and immunoreacted with 1 μg/ml anti-αvβ5 or
anti-αvβ6 integrin mAbs both diluted in 1% BSA. After 3×3 min washing in
PBS, the cells were reacted with rhodamine-conjugated anti-mouse IgG (1:100
in 1% BSA) for 30 min at room temperature, washed 3×5 min in PBS, mounted
on glass slide in 1:1 PBS-glycerol solution and photographed with a Zeiss
fluorescence-Axiovert 10S/H microscope.
The levels of functional integrin receptors distributed on the three tumor cell
lines surface were evaluated by FACS analysis as previously reported [49]. For
each line, 5×105 cells cultured to confluence, completely detached with 0.25%
trypsin and 0.02% EDTA, were washed twice in 0.1% BSA/PBS, centrifuged at
1500 rpm at 4 °C and immunoreacted for 30 min on ice with saturating levels of
anti-αvβ3 (5 μg/ml), anti-αvβ5 (10 μg/ml) integrin mAbs or with anti-αv (1 μg/
ml) and anti-β1 (2 μg/ml) integrin subunits mAbs, diluted in 1% BSA/PBS.
After washing in cold 0.5% BSA/PBS, the cells were reacted with FITC-
conjugated anti-mouse IgG and washed in 0.5% BSA/PBS. The cells were
acquired by FACScan and analyzed by CellQuest software (Becton Dickinson,
San Josè, CA) equipped with a 480 nm argon laser. The same cell strains
immunoreacted with anti-mouse IgG only were used as negative controls.2.5. Western blot analysis
The analysis of FN secreted by the different human tumor cell lines was
performed by 5% SDS-PAGE under non-reducing conditions, followed by
blotting and immunoreaction with f33 anti-FN mAb, as previously reported
[49].
The analysis of αv, β1, β3 and β5 integrins subunits present in the cells
membranes was performed by treating the cells at 4 °C overnight with 0.5%
(v/v) Triton X-100, 20 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, 10 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 10 μg/ml
leupeptin, 4 μg/ml pepstatin and 0.1 KIU/ml aprotinin. Alternatively, β1
integrin subunit was recovered by cell solubilization with a lysis buffer
containing 1% (v/v) Triton X-100, and 50 mM Tris–HCl pH 7.4. After
centrifugation at 14000 rpm, 10 min at 4 °C, the protein concentration was
evaluated by the detergent compatible Bio-Rad DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA) and 2 mg of proteins were immunoprecipitated
with anti-β1, anti-β3, anti-β5, and anti-αv integrin subunit mAbs (10 μg/mg
of protein) for 3 h at 4 °C in the presence of protein G-sepharose beads
(Pierce, Rockford, IL) diluted 1:1 in 150 mM NaCl, 20 mM Tris–HCl pH 7.4
(TBS). The immunocomplexes, recovered by centrifugation and washed, were
boiled in 1% SDS and equal amounts were separated by 8% SDS-PAGE,
transferred to nitrocellulose sheets (Schleicher & Schüell), reacted for 2 h at
room temperature with anti-β1, anti-β3, anti-β5, anti-αv and anti-β1 pS785
(1 μg/ml) antibodies diluted in TBS–0.1% Tween 20 (TBS-T). The β1
immunocomplexes were also reacted with rabbit anti-α1, anti-α2, anti-α5, and
with goat anti-α3 Abs diluted 1:500 in TBS-T. Alternatively, 50 μg crude cell
extracts were immunoblotted with anti-β3 integrin subunit (1 μg/ml) mAb; the
filter stripped and washed was reacted with anti-β3 pY773 phosphospecific
polyclonal antibody (1 μg/ml).
ILK protein was purified by incubating tumor cells 2 h at 4 °C in lysis buffer
(50 mM Tris–HCl pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonylfluoride, 1 μg/ml leupeptin, 1 μg/ml pepstatin and 1 μg/mlaprotinin, 1 mM NaF and 1 mM Na3VO4). One mg of each extract was
immunoprecipitated for 1 h at 4 °C with 4 μg anti-ILK mAb and protein G-
sepharose. After washing in lysis buffer, the immunocomplexes were boiled for
5 min in Laemmli sample buffer [500 mM Tris–HCl pH 6.8, 10% SDS (w/v),
0.05% bromophenol blue (w/v), 0.5% glycerol]. The immunoblotting was
performed by saturating the nitrocellulose membrane in PBS/5% nonfat milk for
3 h at room temperature and incubating overnight at 4 °C with 2 μg/ml anti-ILK
mAb diluted in PBS/5% nonfat milk, or with anti-β1 subunit mAb, as reported
above.
To analyze the secretion of matrix metalloproteinase-9 (MMP-9), the
complete media of untransfected, empty cloning vector and pFN13 plasmid
transfected cell lines were collected 48 h after seeding and concentrated by
Amicon Ultra-15 centrifugal filters (Millipore, Milan, Italy), according to
supplier's instructions. The protein concentration was evaluated by the detergent
compatible Bio-Rad DC Protein Assay and 100 μg of proteins were separated by
10% SDS-PAGE. The immunoblotting was performed by saturating overnight at
room temperature the nitrocellulose membrane in PBS/5% nonfat milk and
incubating for 4 h at room temperature with the rabbit anti-MMP9 polyclonal Ab
recognizing either the pro-form and the active form of the human enzyme
(dilution 1:2000 in PBS/3% nonfat milk). The membranes were incubated with
the horseradish-peroxidase-conjugated anti-mouse or anti-rabbit or anti-goat
IgG and developed by ECL method (Pierce).
2.6. Protein synthesis inhibition by cycloheximide treatment of
tumor cells
1.5×105 untransfected, empty vector and FN13 cloning vector transfected or
exogenously FN13 peptide treated cells, were seeded in complete medium for
3 h to adhere and then supplemented with 1 μg/ml cycloheximide (Sigma
Aldrich, Inc.) for increasing times (from 3 to 48 h), fixed in 3%
paraformaldehyde and immunoreacted with anti-αvβ3 or anti-αvβ5 integrin
mAbs, as reported above.
2.7. Cell invasion assay
1×105 SK-Hep1C3, ACN, SK-OV-3, and ACHN cells untransfected,
transfected with the empty cloning vector or with pFN13 plasmid, or treated
with 40 μg/ml FN13, were suspended in D-MEM containing 10% heat-
decomplemented FBS and added to the upper chamber of Transwell 8 μm filters
(Corning Costar Corp., Cambridge, MA) coated with 150 μg/filter Matrigel
matrix (Becton Dickinson, Bedford, MA) diluted in cold PBS, in the presence or
in the absence of 10 μg/ml αvβ3, αvβ5, or αvβ3 and αvβ5 integrin function
inhibition mAbs or in the presence of human IgG (Sigma Aldrich, Inc.). SK-
Hep1C3 and ACN cells transfected or not were pre-incubated on ice for 30 min
with the function-blocking anti-αvβ3 integrin mAb (clone LM609), SK-OV-3
cells transfected or not, were treated with the anti-αvβ5 (clone P1F6) or with a
mixture of 10 μg/ml anti-αvβ3 and anti-αvβ5 function blocking mAbs.
Conditioned medium from human control fibroblasts, grown in the absence
of FBS, was placed in the lower chamber. The assays were carried out at 37 °C in
5% CO2 atmosphere for 48 h. The Matrigel and the non-invasive cells were
removed from the upper face of the Transwells with a cotton swab and the filters
and dishes were fixed in cold methanol and stained with 5% (v/v) Giemsa. All
the cells migrating on the bottom of the filters and in the lower chambers were
counted at 600× magnification. Each assay was performed in triplicate and
repeated in three independent experiments; the averages±standard deviation
(S.D.) were calculated and statistical analysis was performed by Student's two-
tailed t-test.3. Results
3.1. Identification of human tumor cell lines organizing the
FN-ECM following FN13 peptide treatment.
The activity of the synthetic FN13 peptide was studied on
three cell lines, one of mesenchymal origin (SK-Hep1C3, a
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ectodermic origin (ACN, neuroblastoma, SK-OV-3, ovary ade-
nocarcinoma). All these cell lines did not organize the FN-ECM
as detected with the f33 mAb IF, from 48 h (Fig. 1A) to 8 days
culture (Supplementary Material 1 to Fig. 1A). After 48 h
treatment with purified FN13, the three tumor cell lines
organized to a different extent an FN-ECM (Fig. 1A). SimilarFig. 1. FN13 peptide induces the organization of FN in human tumor cell lines (A), se
plasma hFN in multimers (C). (A) The FN-ECM was detected by IF analysis with the
10 μm. (B) Evaluation of FN present in the conditioned medium of human tumor cel
(C) FITC-hFN incubated in the absence (FN) and in the presence of FN13 (FN13) or
Scale bar, 12 μm.results were obtained using an anti-human FN polyclonal Ab
(Supplementary Material 2 to Fig. 1A).
The capability of organizing the FN-ECM after FN13 treat-
ment could not be ascribed to the levels of FN secreted into
the culture medium in the different cell lines, since SK-
Hep1C3 cells, secreting low levels of FN (Fig. 1B), organized
an FN-ECM richer than SK-OV-3 and ACN cells secretingcreting variable amounts of FN (B) and the aggregation of FITC-labelled purified
f33 anti-FN mAb in cells treated or not with 40 μg/ml FN13 for 48 h. Scale bar,
l lines, detected by Western blotting with the f33 anti-FN mAb. FN: 10 μg hFN.
scrambled FN13 peptide (ScrFN13) was detected by a fluorescence microscope.
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tected in these conditions (Fig. 1B). The absence of an
organized FN network in these cell lines secreting the protein
suggested the possible reduction of specific integrin receptors
on their surfaces.
In order to understand the molecular mechanism by which
FN13 peptide induced the organization of FN-ECM in defective
tumor cell lines, we investigated the effect of FN13 on FITC-
labelled purified hFN. Whereas hFN was not capable of in vitro
self-organization, it gave rise to the formation of large and thick
multimers in the presence of FN13 (Fig. 1C). These hFN
aggregates were not obtained when FN was treated with an
FN13 scrambled peptide (ScrFN13), indicating that FN13
sequence retains the capability to organize hFN in an acellular
system.
3.2. Construction of pFN13 vector and stable expression of
FN13 peptide in tumor cell lines
A 144-bp minigene encoding the FN secretion signal
sequence followed by the 13 amino acids of FN13 peptide
(pFN13) (Fig. 2A), was transfected in SK-Hep1C3, ACN, and
SK-OV-3 cell lines. After blasticidine selection, the stable
transfectants SK-Hep1C3pFN13, ACNpFN13 and SK-OV-
3pFN13 were analyzed for plasmid expression and integra-
tion. RT-PCR analysis of total RNAs purified from untrans-
fected and transfected cell lines showed that only the cells
transfected with pFN13 expressed the FN13 mRNA, corre-
sponding to the 253 bp fragment, as detected by agarose gel
electrophoresis (Fig. 2B). A 201 bp fragment, corresponding
to the transcript from the empty vector, was detected only in
cells transfected with the empty vector (Fig. 2B). The same
patterns were obtained on RNAs purified from cells main-
tained in culture for several in vitro passages. PCR analysis
with the same primers used for RT-PCR, on genomic DNA
purified from the different cell lines gave the same
amplification products (not shown). These data demonstrate
that the plasmids used for transfection were stably integrated
into the genomic DNA and that the pFN13 transfectants
expressed the FN13 transgene.
3.3. Stably expressed FN13 peptide induces the FN-ECM
organization in tumor cells
SK-Hep1C3pFN13, ACNpFN13 and SK-OV-3pFN13 sta-
bly expressing FN13 peptide, analyzed by IF microscopy with
the f33 anti-FN mAb, organized the FN-ECM, whereas the cells
transfected with the empty cloning vector, as well as their
untransfected counterparts reported in Fig. 1A, did not organize
the fibrillar FN-ECM (Fig. 2C). The morphology and
abundance of the FN-ECMs in the three pFN13 transfectants
were similar to those obtained treating the untransfected tumor
cell lines with purified FN13 peptide (Fig. 1A). Therefore,
FN13 peptide, either exogenously added into the culture
medium or stably expressed by the transfected tumor cells,
induces the FN-ECM organization in SK-Hep1C3, ACN and
SK-OV-3 defective cell lines.3.4. FN13 peptide induces the organization of αvβ3 or αvβ5
FNRs in tumor cells
The FN receptors (FNRs) organization in the different
pFN13 transfectants was analyzed by IF and compared with that
of the empty vector transfected counterparts. SK-Hep1C3,
ACN, and SK-OV-3 cell lines did not organize the αvβ3
integrin when transfected with the empty vector (Fig. 3A).
Following pFN13 transfection, SK-Hep1C3 and ACN orga-
nized αvβ3 integrin, whereas SK-OV-3 cells organized
increased levels of αvβ5 integrin, compared to the empty
vector transfected counterpart (Fig. 3A). Untransfected tumor
cells showed an αvβ3 and αvβ5 pattern (not shown)
comparable with that of their counterparts transfected with the
empty vector (Fig. 3A). The treatment of the untransfected
tumor cells with purified synthetic FN13 peptide exogenously
added to the culture media induced an organization of αvβ3 and
αvβ5 integrins comparable with that observed in the pFN13
transfected cells (Supplementary Material to Fig. 3). The IF
results were confirmed by FACS analysis performed with anti-
αvβ3 and anti-αvβ5 integrins mAbs on the different transfec-
tants, compared to the empty vector transfected cells (Fig. 3B–
D). In the FN13 expressing tumor cells very low amounts of
α5β1 integrins were detected by IF analysis, the αvβ6 integrins
were not detected (not shown).
Western blotting analysis of αv and β3 integrin subunits,
performed on β3 immunoprecipitates, obtained from the three
tumor cell lines in the different conditions, was performed
reacting with specific anti-αv and anti-β3 mAbs. Fig. 4A shows
that β3 integrin subunit was detected only in SK-Hep1C3 and
ACN cells transfected with pFN13, and that this subunit was
bound to the αv subunit. These data confirm the presence of
αvβ3 integrin patches, detected by IF and FACS analysis in SK-
Hep1C3 and ACN cells transfected with pFN13.
The β5 integrin subunits immunoprecipitates were detected
by Western blotting analysis only in SK-OV-3 cells either
untransfected or transfected with the empty cloning vector and
pFN13 recombinant vector (Fig. 4B). In these cells the β5
integrin subunits were bound to the αv subunits, as detected by
immunoreaction of β5 immunoprecipitates with an anti-αv
mAb. In SK-OV-3 cells expressing FN13 peptide, an increase of
αv and β5 integrin subunits was detectable (Fig. 4B). These
data confirm the presence of αvβ5 integrin patches, detected by
IF and FACS analysis in SK-OV-3 cells and the increase of this
dimer in cells transfected with pFN13.
The β3 integrin subunit was detected also in crude SK-
Hep1C3pFN13 and ACNpFN13 cell extracts and was found to
be phosphorylated at the tyrosine 773 of the cytoplasmic tail
(Fig. 4C), thus indicating its involvement in signal transduction.
These data indicate that in these cells the FN13-induced αvβ3
integrins are involved in signal transduction.
3.5. Effect of cycloheximide on αvβ3 and αvβ5 integrins
organization
We investigated the effect of cycloheximide on the orga-
nization of αvβ3 and αvβ5 integrins in the different tumor
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αvβ5 mAbs. The αvβ3 and αvβ5 integrins were maintained
in the plasma membranes of the different tumor cell lines
expressing FN13 or treated with the purified peptide until
12 h of treatment and were progressively disorganizing from24 to 48 h of treatment (Fig. 5 and Supplementary Material 1
to Fig. 5).
In the three tumor cell lines variable basal levels of the α5,
αv, β1, β3, and β5 integrin subunits mRNAs were detected by
quantitative RT-PCR (not shown). The stable expression of
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of the levels of all integrin subunits, as detected by quantitative
RT-PCR (Supplementary Material 2 to Fig. 5). These data
suggest that the regulation of integrins organization mainly
occurs in the three pFN13 transfected cell lines at post-
transcriptional level.
3.6. αvβ3 and αvβ5 integrins organization is associated with
αvβ1 disorganization and ILK pathway switch off
We investigated whether the αv integrin subunit, constitu-
tively expressed by SK-OV-3 cells and induced by FN13 in SK-
Hep1C3 and ACN tumor cell lines (Figs. 3 and 4), could
interact with β1 integrin subunit, forming the αvβ1 integrin,
another FN receptor. At first, FACS analysis was performed on
the different tumor cell lines. For this purpose, since an anti-
αvβ1 antibody was not available, the analysis was performed
reacting the cells with an anti-αv and an anti-β1 integrin
subunit mAb. Fig. 6A shows that the number of pFN13
transfectants organizing the β1 subunit was reduced by about
4-fold in SK-Hep1C3 and ACN cells and by 13-fold in SK-
OV3 cells, compared to the empty vector transfected and the
untransfected cells (not shown). On the contrary, the αv subunit
was organized in about 80% of the FN13 transfected tumor cell
lines (Fig. 6A).
Western blotting analysis of β1 immunoprecipitates from the
different tumor cells were reacted either with anti-β1 or anti-αv
mAbs. β1 subunit was present in all the untransfected and
empty vector transfected tumor cell lines; in SK-Hep1C3pFN13
cells, β1 was present at low level, and in ACNpFN13 and SK-
OV-3pFN13 cells it was absent (Fig. 6B). The β1 subunits were
phosphorylated at the 785 serine residue in the cytoplasmic tail
(Fig. 6C). In all the untransfected and empty vector transfected
cells the β1 subunit co-immunoprecipitated with the αv subunit
(Fig. 6B). The Western blotting analysis of the αv immunopre-
cipitates showed that this integrin subunit was expressed by all
tumor cell types and it was bound to the β1 subunit in all cell
types with the exception of ACNpFN13 and SK-OV-3pFN13
cells (Fig. 6D). The β1 subunit immunoprecipitates, obtained at
high detergent concentrations and with a different mAb (clone
BV7), confirmed that β1 subunit were expressed by all cell
types, but not by ACNpFN13 and SK-OV-3pFN13 cells (Fig.
6E). The Western blotting analysis of these β1 immunopreci-
pitates reacted with anti-α1, anti-α2, anti-α3, anti-α5 poly-
clonal Abs, and with anti-αv integrin subunits mAb, showed
that the β1 subunits were bound to the α1 subunit only in SK-Fig. 2. Cloning and stable expression of FN13 minigene lead to the organization of the
strategy to generate a plasmid expressing the 13 amino acid FN peptide (pFN13).
genomic clone pgHF3.7 [48] containing the 5′ end of FN gene as template: the 5′ pri
consensus sequence and the translation start codon; the 3′ primer contained a translat
translation with the codon usage table (Entelechon) and the 3′ end of the FN signal
pEF6/V5-His-TOPO™ expression vector to generate the pFN13 plasmid. The dotted
promoter. (B) Tumor cells transfected with pFN13 express FN13 mRNA, as detected
fragments show the expression of the empty vector and the pFN13 recombinant vecto
M: DNA size marker. (C) Tumor cells transfected with pFN13, but not with the empt
the f33 anti-FN mAb. Scale bar, 8 μm.Hep1C3pFN13 cells (Fig. 6E). β1 subunit was not bound to the
α2 subunit in any of the tumor cell lines and was bound to the
α3 subunit only in SK-OV-3 untransfected and empty vector
transfected cells. Low levels of α5 subunit were bound to β1
immunoprecipitates in all cell types with the exception of
ACNpFN13 and SK-OV-3 cells. Also in these immunopreci-
pitation conditions, the β1 subunits, were mainly bound to the
αv subunit in all untransfected and empty vector transfected
cells, but not in pFN13 transfected cells lines (Fig. 6E). Taken
together these data show that in the cells not expressing FN13
peptide the αvβ1 dimers are present as the most abundant
β1-containing integrins and that the FN13 expression induces,
in all tumor cell lines tested, the downloading of αvβ1
integrins. This event is associated in SK-Hep1C3pFN13 and
ACNpFN13 transfectants to the organization of β3 subunit
recruiting the αv chains. In SK-OV-3pFN13 cells the αvβ1
integrin down-regulation is associated with the increase of
αvβ5 integrin organization. The SK-HepC3pFN13 cells were
also induced to organize α1β1 and maintained to a lower
extent α5β1 dimers.
The αvβ1 integrins detected in all tumor cell lines were
bound to ILK protein, as demonstrated by co-immunoprecipita-
tion of β1 integrin subunit with ILK (Fig. 7A). On the contrary,
the transfectants expressing FN13, which organized αvβ3 or
αvβ5 integrins, showed not only the strong reduction or the
absence of β1 subunits, but also the absence of ILK (Fig. 7A).
The ILK decrease was observed also in the crude cell extracts
from the three FN13 expressing transfectants (not shown). The
down-regulation of ILK organization in all pFN13 transfectants,
compared to the control counterparts was confirmed by IF
analysis (not shown).
These data show that the organization of αvβ3 and αvβ5
integrins, consequent to FN13 peptide expression, is associated
with the disorganization of αvβ1 dimers and the dissociation of
β1-ILK complexes.
In order to investigate the effect of αvβ1-ILK dissociation
on the β1-ILK-mediated signal transduction pathway, the levels
of a major downstream ILK target, the MMP-9, were analyzed
by Western blotting. Fig. 7B shows that MMP-9 was expressed
and released in the culture media of untransfected and empty
vector transfected cell lines, but was undetectable in all pFN13
transfected cell lines. In the cells expressing MMP-9, the
inactive 95 kDa pro-enzyme was present at lower levels than the
82 kDa active form. These data show that in tumor cells
expressing FN13 peptide and organizing αvβ3 or αvβ5 integrin
ILK signalling is inactivated.FN-ECM in human tumor cell lines. (A) Schematic representation of the cloning
(a) Two primers were used to construct the FN13 mingene by PCR on the FN
mer corresponded to the 5′ end of human FN signal peptide including the Kozak
ion stop codon, the 39 nucleotides encoding the FN13 peptide obtained by back-
peptide sequence. (b) The PCR product was directly ligated into the eukaryotic
arrow shows the direction of transcription regulated by the PEF-1α constitutive
by RT-PCR analysis and agarose gel electrophoresis. The 201 bp and the 253 bp
r mRNAs, respectively. The 407-bp fragment corresponds to the HPRT mRNA.
y vector, organize the FN-ECM. The FN-ECM was detected by IF analysis with
Fig. 3. FN13 induces the organization on the cell membranes of FNR integrins in SK-Hep1C3, ACN and SK-OV-3 tumor cells, as detected by IF (A) and FACS
analysis (B–D). IF microscopy was performed on empty vector and pFN13 transfected tumor cells with anti-αvβ3 and anti-αvβ5 mAbs. Scale bar, 8 μm (A). FACS
analysis histograms (B, C) and percent evaluation (D) of the αvβ3- and αvβ5-positive cells.
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Fig. 4. FN13 expression induces the organization of αvβ3 FNR integrins in SK-
Hep1C3 and ACN pFN13 transfected tumor cells (A) and of increased amounts
of αvβ5 FNR integrins in SK-OV-3 pFN13 transfected cells (B), as detected by
Western blotting of β3 and β5 immunoprecipitates reacted with anti-αv, anti-β3
and anti-β5 integrin subunits mAbs. In panel C reported is the induction of β3
integrin subunit and its tyrosine 773 phosphorylation in SK-Hep1C3 and ACN
pFN13 transfected cells, evaluated in crude cell extracts.
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decrease Matrigel invasion
The three transfectants stably expressing FN13 peptide,
organizing the FN-ECM and up-regulating the αvβ3 and αvβ5
integrin receptors organization, were analyzed for their invasive
potential in Matrigel matrix. The invasion of SK-Hep1C3pFN13Fig. 5. Effect of cycloheximide treatment on the αvβ3 and αvβ5 integrin organiza
untransfected and transfected with the empty cloning vector or with pFN13, or treated
in the absence or in the presence of 1 μg/ml cycloheximide and analyzed by IF withand ACNpFN13 cell lines were about 7- and 11-fold respectively
inhibited, compared to the corresponding cells transfected with the
empty vector (Fig. 8). On the contrary, the SK-OV-3pFN13 cells
did not show a significant inhibition of their invasive potential,
compared to the cells transfected with the empty vector. Similar
results were obtained in the three tumor cell lines treated with
purified FN13 (not shown). Therefore, the cells, in which the
organization of αvβ3 integrins was induced, reduced their invasive
potential, whereas the SK-OV-3pFN13 cells, organizing the αvβ5
integrins, maintained their invasive properties.
The role of αvβ3 and αvβ5 integrins in cell invasion was
analyzed in the FN13 expressing cells, by integrin functional
inhibition with mAbs directed against the FN-binding site of
these integrins. The inhibition of αvβ3 integrin in SK-
Hep1C3pFN13 and in ACNpFN13 cells downloaded the
organization of αvβ3 integrins (Supplementary Material to
Fig. 9A) and restored Matrigel invasion by about 5- and 8-fold,
respectively, compared to the cells not inhibited (Fig. 9A),
indicating that the αvβ3 integrin prevents Matrigel invasion in
these two cell lines in the presence of FN13 peptide. The
functional block of αvβ5 integrin in SK-OV-3 cells stably
expressing FN13 induced a 12-fold inhibition of the Matrigel
invasion, compared to the not inhibited cells (Fig. 9B).
Following this treatment, the cells did not organize the αvβ5
integrin but rather the αvβ3 integrins, as detected by IF (Fig.
10A) and FACS analysis (Fig. 10B, C, and Supplementary
Material to Fig. 10). Functional block of αvβ5 integrin in SK-
OV-3 cells untransfected and transfected with the empty vector
slightly inhibited (about 2-fold) their invasive potential (Fig.
9B), but did not induce αvβ3 integrin organization (not shown),tion in SK-Hep1C3 and SK-OV-3 tumor cell lines. The two tumor cell lines,
with 40 μg/ml exogenously added synthetic FN13 peptide, were grown for 48 h
anti-αvβ3 and anti-αvβ5 specific mAbs. Scale bar, 3 μm.
Fig. 6. FN13 induces the disorganization of αvβ1 FNR integrins in the three pFN13 expressing tumor cell lines, as detected by FACS analysis (A), and Western
blotting analysis of β1 immunoprecipitates obtained with two different mAbs (B, clone K20, from Santa Cruz; E, clone BV7 from Abcam), reacted either with anti-αv
and the two different anti-β1 integrin subunits mAbs (B, E) or with anti-α1, anti-α2, anti-α3, and anti-α5 integrin subunits Abs (E). In the Table reported in panel A,
the numbers are the percent evaluations of the αv- and β1-positive cells. In panel C reported is the serine 785 phosphorylation of β1 integrin subunit analyzed on β1
subunits immunoprecipitates of untransfected, empty vector and pFN13 transfected tumor cells. In panel D reported is the Western blotting analysis of αv integrin
subunits immunoprecipitates and of the β1 subunits binding to the αv subunit, in the different tumor cell lines.
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Fig. 7. FN13 downloads β1-bound ILK protein in tumor cell lines, as detected
by Western blotting of ILK immunoprecipitates reacted with anti-ILK and anti-
β1 integrin subunit mAbs (A). pFN13 transfected tumor cells inactivate ILK-
mediated signalling, as demonstrated by the absence in the medium of the pro-
form (95 kDa band) and the active form (82 kDa band) of MMP-9 (B), as
detected by Western blotting of 100 μg of proteins recovered in conditioned
media of each tumor cell line.
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invasion process in these cells.
These data indicate that the inhibition of Matrigel invasion is
associated with the organization of αvβ3 integrin in cells
expressing FN13 peptide. The role of αvβ3 integrin in the
prevention of SK-OV-3pFN13 Matrigel invasion was con-
firmed by its inhibition with a specific mAb. In the presence of a
mixture of αvβ5 and αvβ3 functional blocking mAbs, SK-OV-
3pFN13 transfectants did not decrease their invasive potential,
compared to their untreated counterparts (Fig. 9B).Fig. 8. Effect of stably expressed FN13 peptide on the invasion of human tumor
cell lines. Invasion assay on Matrigel matrix was performed with equal number
of SK-Hep1C3, ACN and SK-OV-3 cells untransfected, transfected with the
empty cloning vector or with pFN13. The invasion inhibition was about 7-fold
in SK-Hep1C3 and 11.0-fold in ACN pFN13 transfected tumor cells versus the
empty vector transfectants. No significant invasion inhibition was detected in
SK-OV-3pFN13 tumor cells. The values reported are the average±S.D. of the
measurements performed in triplicate in three independent experiments. The
statistically significant p values, obtained by Student's two-tailed t-test are
indicated by the asterisks (***p<0.001, pFN13 versus empty vector transfected
cells).3.8. The αvβ5-αvβ3 integrins switch induced by αvβ5
functional inactivation is a common mechanism
In order to investigate whether the αvβ5–αvβ3 integrin
switch induced by Ab-mediated αvβ5 function block, might be
a common mechanism, the effect of Ab-mediated αvβ5
inhibition in another tumor cell line (ACHN) organizing theFig. 9. Blocking of αvβ3 integrin function with a specific mAb enhances the
Matrigel matrix invasion of SK-Hep1C3pFN13 and ACNpFN13 tumor cells
(A), whereas blocking of αvβ5 integrin function with a specific mAb inhibits
the invasion of SK-OV-3pFN13 tumor cells (B). (A) The values reported are the
average±S.D. of the measurements performed in triplicate in three independent
experiments. The statistically significant p values, obtained by Student's two-
tailed t-test, in the different tumor cells are indicated by the asterisks
(***p<0.001; anti-αvβ3 treated versus untreated cells). (B) The invasion
inhibition, induced by treating SK-OV-3pFN13 cells with function blocking
anti-αvβ5 mAb, is abolished blocking the transfectants with anti-αvβ5 and anti-
αvβ3 mAbs. The values reported are the average±S.D. of the measurements
performed in triplicate in three independent experiments. The statistically
significant p values, obtained by Student's two-tailed t-test are indicated by the
asterisks (***p<0.001; **p<0.01; *p<0.05; anti-αvβ5 mAb treated versus
untreated cells). In A and B the treatment of each tumor cell line with irrelevant
human IgG (hIgG) is reported, as control of the specific function blocking of
anti-αvβ3 and anti-αvβ5 mAbs.
Fig. 10. Blocking of αvβ5 integrin function with a specific mAb induces in SK-OV-3pFN13 cells the organization of αvβ3 integrin, as detected by IF (A) and FACS
(B, C) analysis. In panel A the SK-OV-3pFN13 cells recruit αvβ3 integrins, after αvβ5 integrin blocking. Scale bar, 6 μm. In panels B and C reported are the FACS
histograms and the percentage of SK-OV-3pFN13 cells expressing αvβ5 and αvβ3 integrins, respectively, before and after treatment with anti-αvβ5 integrin function
blocking mAb.
758 N. Zoppi et al. / Biochimica et Biophysica Acta 1773 (2007) 747–763αvβ5 integrin was analyzed. Renal carcinoma derived ACHN
cells, when treated with exogenously added FN13, organized
the FN-ECM (Fig. 11A). Untreated ACHN cells organized the
αvβ5, but not the αvβ3, integrin receptor (Fig. 11B). Following
FN13 treatment, the cells organized low levels of αvβ3 in
addition to αvβ5 integrins. Treatment with anti-αvβ5 integrin
mAb, either in the presence or in the absence of FN13, induced
the disorganization of αvβ5 and the parallel increase of αvβ3
integrin patches (Fig. 11B). In ACHN cells, therefore, the
organization of αvβ3 integrin can be induced either by FN13 or,as in the case of SK-OV-3pFN13 cells, by αvβ5 functional
inhibition. These data suggest that after the αvβ5 integrin
functional inhibition, the organization of the αvβ3 integrin
should be a recurrent event.
The invasive potential of ACHN cells, in the different
conditions reported in Fig. 11B, was analyzed in Matrigel
matrix (Fig. 11C). The treatment of ACHN cells with FN13
peptide, inducing the organization of αvβ3 integrin (Fig. 11B)
and of the FN-ECM (Fig. 11A), inhibited by about 2-fold the
cell invasion of ACHN cells. In FN13-treated cells, maintained
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complete disorganization of αvβ5 integrin and the organization
of αvβ3 integrin (Fig. 11B), the Matrigel invasion was inhibited
by about 8-fold (Fig. 11C). In FN13-untreated cells, the
functional inhibition of αvβ5 integrin did not modulate the
invasive potential of ACHN cells, suggesting that in this cell
line αvβ5 integrin is not directly involved in in vitro invasion.
Furthermore, these αvβ3+ ACHN cells, in the absence of an
organized FN-ECM (not shown), maintained their invasive
potential (Fig. 11C), thus suggesting that tumor cell invasion is
inhibited in cells organizing the FN13-induced FN-ECM and
αvβ3 integrins. The simultaneous inhibition of αvβ5 and αvβ3
integrins with specific mAbs, induced in FN13-treated ACHN
cells the almost complete recovery of their invasive potential
(Fig. 11C). These data show that also in this tumor cell line, the
αvβ3, but not αvβ5 integrins, in the presence of FN13, exerts
an anti-invasive role in Matrigel matrix.
4. Discussion
In this work we report that FN13 peptide induces the
organization of the FN-ECM in three human tumor-derived cell
lines defective for the FN-ECM organization. These cell lines
were transfected with an expression vector carrying the FN13
minigene. The three transfectants stably expressing and
secreting FN13 peptide organized an FN-ECM comparable
with that induced by exogenously added purified FN13 peptide.
Therefore, FN13 peptide is capable of inducing the assembly of
the FN-ECM in responsive tumor cell lines either when stably
expressed or exogenously added to the cell culture medium.
FN, synthesized to different extent by the tumor cell lines
analyzed and secreted in the culture medium, in the absence of
FN13, did not assemble into the ECM probably as a
consequence of the poorly organized integrin receptors on the
plasma membrane of untreated tumor cells. Reduction or
absence of the FN-ECM and FNR integrins has been reported in
several tumor cell lines [2,11–15]. FN secreted by the tumor
cells analyzed was organized in an ECM-like structure by FN13
peptide. The FN-ECM assembly induced by the peptide, stably
expressed or exogenously added in tumor cells, did not depend
on the levels of FN secreted in long-time cultures (8 days).
FN13 peptide was capable of organizing purified hFN and of
generating large aggregates also in acellular conditions. A
similar FN in vitro linking activity was also reported for the
hFN peptide anastellin [32]. These data support the hypothesis
that FN13 acts in the extracellular environment linking FN
secreted by the different tumor cells, instead of binding to a cell
surface receptor. Since FN13 does not contains an RGD
sequence, it is unlikely that it is capable of binding integrins.
The FN-ECM organized by the different tumor cell lines should
differ from the FN-ECM assembled by control cells, organized
in the absence FN13 peptide.
In the three tumor cell lines stably expressing FN13, or
grown in its presence, the peptide was capable of inducing
modifications not only at the extracellular but also at the
intracellular level. These cell lines at the intracellular level
lacked the integrin-linked kinase (ILK), known to act as a potentβ-integrin subunits bound effector in several cancers [41]. In the
untransfected and empty vector transfected tumor cells ILK co-
immunoprecipitated with phosphorylated β1 integrin subunit
which was forming αvβ1 integrin dimers. Since in pFN13
transfected cells αvβ1 integrins were undetectable, ILK down-
loading was induced by FN13 peptide, through αvβ1 dis-
organization. In these cells these events led to the inactivation of
the specific ILK pathway, ultimately downloading the MMP-9
secretion. Since this enzyme, through the degradation of several
ECM components, favours tumorigenic cells invasion [41], we
analyzed the invasive properties of the different tumor cell lines
not expressing or expressing FN13 peptide in Matrigel matrix.
SK-Hep1C3pFN13 and ACNpFN13 transfectants showed a
significant reduction of their invasive potential, compared to
their untransfected counterparts; whereas the SK-OV-3pFN13
cells did not significantly reduce their invasive behaviour.
Despite ILK downregulation, in pFN13 transfected tumor
cells, the inhibition of the invasion was not associated with the
inhibition of proliferation. Indeed, the proliferation inhibition of
FN13 transfected cells, compared to the empty vector
transfected counterparts, starting from 48 h after seeding, was
about 80% for SK-Hep1-C3pFN13, 20% for ACNpFN13 and
SK-OV-3pFN13 cells (not shown).
In order to elucidate the different invasive behaviour of the
three tumor cells lines, in front of the common ILK pathway
inactivation, we hypothesized that this could depend on the
different FN integrin receptors profile, elicited by the FN13
induced FN-ECM. We observed, by means of different
experimental approaches, that the FN-ECM assembly induced
by FN13 elicited the organization of αvβ3 integrins in SK-
Hep1C3 and ACN cells and of higher levels of αvβ5 integrins
in SK-OV-3 cells. We observed that in the αvβ3+ cells the β3
subunit was activated by the tyrosine 773 phosphorylation.
Protein synthesis inhibition with cycloheximide and quantita-
tive RT-PCR on the different integrin subunits mRNAs
indicated that the regulation of integrins organization in the
three tumor cell lines expressing FN13 mainly occurred at post-
transcriptional level. In addition to the αvβ3 FNR integrin, the
SK-Hep-C3pFN13 cells organized only the α1β1 collagen
receptor; a small amount of α5β1 FNR was likely organized by
all cell types not expressing FN13 and by SK-Hep1C3pFN13
cells. The presence in SK-Hep1C3pFN13 cells of the α1β1
integrin suggests that these cells could organize into the ECM
not only FN, but also collagens and laminins [7].
The Ab-mediated function block of αvβ3 integrins restored
in SK-Hep1C3pFN13 and ACNpFN13 cells the same invasive
potential of their untransfected counterparts. These data indicate
that the αvβ3 integrin, binding the FN13-induced FN-ECM, is
involved in the inhibition of in vitro invasion of these cells.
Since SK-OV-3pFN13 cells, organizing only the αvβ5
integrin, maintained a high invasive potential, we hypothesized
that this integrin was directly involved in this process. In order
to confirm this hypothesis, we treated SK-OV-3 cells with an
anti-αvβ5 function blocking mAb. In the absence of organized
αvβ5 integrins, the untransfected and empty vector transfected
cells slightly reduced their invasive potential, whereas pFN13
transfectants showed a marked reduction of invasion. Since the
Fig. 11. αvβ5-positive ACHN renal tumor cells are induced to organize the FN-ECM (A) and αvβ3 integrin after treatment with FN13 peptide, or with FN13 in the
presence of function block αvβ5 integrin mAb (B). The effect of these treatments in the Matrigel matrix invasion is reported in panel C. (A) The FN-ECMwas detected
by IF analysis with the f33 anti-FN mAb in cells treated or not with 40 μg/ml FN13 for 48 h. Scale bar, 10 μm. (B) The αvβ5 and αvβ3 integrins organization was
detected by IF analysis with specific mAbs after a 48 h treatment with FN13 peptide and/or function blocking anti-αvβ5 mAb. Scale bar, 6 μm. (C) The cell invasion,
downloaded by treating ACHN cells with 40 μg/ml FN13, is almost abolished blocking the FN13-induced cells with the anti-αvβ5 mAb, whereas it is restored by the
treatment with a cocktail of function blocking anti-αvβ5 and anti-αvβ3 mAbs. The incubation of ACHN cells, treated or not with FN13, with human IgG (hIgG) is
reported as control of the specific function blocking of anti-αvβ3 and anti-αvβ5 mAbs. The values reported are the average±S.D. of the measurements performed in
triplicate in three independent experiments. The statistically significant p values, obtained by Student's two-tailed t-test, are indicated by the asterisks (***p<0.001,
FN13 peptide treated versus untreated cells).
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Fig. 11 (continued).
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induced the organization of αvβ3 integrins, we concluded that
also in these cells the invasion reduction was associated with the
organization of αvβ3 integrin at the plasma membrane level.
The involvement of αvβ3 integrin in Matrigel invasion in-
hibition, in all cells expressing the FN13 peptide, was confirmed
by the recovery of their invasive potential following αvβ3
integrin function inhibition with a specific anti-αvβ3 mAb.
Taken together these data show that FN13 peptide, through
the formation of the FN-ECM, acts on three different tumor cell
lines modulating their FNR integrin pattern, and lead to β1
subunits-ILK dissociation, to MMP-9 downloading and to a
significant invasion reduction when αvβ3, but not αvβ5,
integrins were organized.
In order to evaluate whether the switch of αvβ5 to αvβ3
integrins induced by Ab-mediated function block of αvβ5
integrin was a common mechanism, we analyzed the effect of
this treatment on ACHN renal tumor cell line, organizing αvβ5
integrin patches. Also in these cells the αvβ5 function
inhibition gave rise to the organization of αvβ3 integrins,
even in the absence of FN13, thus indicating that the αvβ5 to
αvβ3 switch should be a recurrent event. These results also
indicate the existence of a hierarchy in integrins clustering,
αvβ3 being an integrin which can be recruited when αvβ5 is
disorganized. Since ACHN cells, organizing αvβ3 integrin after
αvβ5 inhibition, significantly reduced also their invasive
potential in Matrigel matrix only in the presence of FN13,
these data underline once more the anti-invasive effect exerted
by FN13 in combination with αvβ3 integrins in tumor cells.
It must be noticed that integrin remodelling in cultured tumor
cell lines is a common event which mainly depends on different
culture conditions and selection. SK-OV-3 tumor cells integrin
profiles have been studied in relationship with cell migration and
proliferation in previous studies [50–52]. Though these cells
were initially reported to organize αvβ3 integrins [50], in
following studies they were shown to undergo integrins setting
changes, in particular, to organize also αvβ5 and to reduce α5β1
integrins [51,52]. In this work the SK-OV-3 cells were checked
to maintain, in the different experimental conditions, theircharacteristic organization of αvβ5 integrins, but did not
organize the αvβ3 dimers. This integrin pattern was changing
only after αvβ5 integrins Ab-mediated function block and in the
presence of FN13, which induced, in repeated experiments, the
disorganization of αvβ5 and the organization of αvβ3 integrins.
In SK-OV-3 tumor cells, FN13 elicits the up-regulation of
αvβ5 integrin organized on the plasma membrane. This integrin
is known to bind as major ligand vitronectin, and, only as minor,
FN [3,5,6], and, in the absence of other FN-binding integrins,
supports the FN-ECM assembly in these cells. This anomalous
binding specificity of αvβ5 integrins is likely due to the FN-
ECM induced by FN13 peptide which differs from the fibrillar
FN-ECM organized by normal cells [7].
The anti-invasive role of FN13 in association with the αvβ3,
but not the αvβ5, FNR integrins could be ascribed to a different
adhesive potential of the two integrins to the Matrigel matrix
components, or to a different capability of these integrins to
organize the FN13-induced FN-ECM on the top of Matrigel
matrix immediately after loading the cells in the Transwell
chamber. The association of αvβ5 integrin organization with
the invasive tumor cells properties observed in SK-OV-3pFN13
cells, in the absence of an active ILK signalling, remains to be
further investigated.
In conclusion, our results show that FN13 peptide plays a
role in tumor cells invasion inhibition through the induction of
an FN-ECM organization, the dissociation of αvβ1 dimers,
leading to ILK pathway inactivation, and through the induction
of αvβ3 integrins binding to the FN-ECM.
Since many evidences underline the positive role of αvβ3
integrin in tumorigenicity [30–40,53], our data suggest that
several highly tumorigenic cell types constitutively organizing
the αvβ3 integrin might be a target for FN13 treatment. The
data here reported suggest a possible application of FN13 in
gene therapy or in pharmacological treatment for the inhibition
of the invasive properties of αvβ3 positive tumor cells,
considering that, due to its evolutionary conserved sequence,
FN13 peptide is not immunogenic. The possible role of αvβ3
integrins induced by FN13 in in vivo tumor invasion inhibition
is in progress.
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